Cytokinetics Inc (CYTK) stock
Close on Nov 11, 2026Market cap $8.14BP/E –Yield –
Cytokinetics Inc grew revenue 29.9% to $113.29M over the twelve months to Sep 30, 2026. Free cash flow was -$588.58M. At the latest close the market valued the company at $8.14B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $8.14B
- P/E ratio
- –
- Price to sales
- 71.82
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -7.23%
Fundamentals
- Revenue
- $113.29M
- Net income
- -$777.89M
- EPS, diluted
- -$6.54
- Free cash flow
- -$588.58M
- Book value per share
- -$2309.83
- Diluted shares
- 0M
Trading
- Next earnings
- Feb 23, 2027 (estimated, after the close)
- Previous close
- $56.18
- Open
- $56.40
- Day's range
- $55.74 – $59.08
- Volume
- 2,811,699
- Average volume (20 days)
- 1,982,703
- Index membership
- S&P MidCap 400 (since May 2024), Russell 2000, Russell 3000
- Beta (5 years)
- 0.86
- 52-week range
- $53.55 – $88.31
- RSI (14 days)
- 42.9
- Volatility (1 year)
- 43.9%
- Relative volume
- 1.44×
- WACC
- 9.0%
Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CYTK | S&P 500 | Difference | CYTK per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.0% | -2.4% | −4.6 pts | ||
| 3 months | -23.4% | -1.2% | −22.3 pts | ||
| Year to date | -7.9% | +12.3% | −20.2 pts | ||
| 1 year | -12.0% | +12.4% | −24.4 pts | ||
| 3 years | +80.1% | +78.8% | +1.3 pts | +21.7% | +21.4% |
| 5 years | +48.1% | +75.2% | −27.0 pts | +8.2% | +11.9% |
| 10 years | +422.6% | +311.1% | +111.5 pts | +18.0% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cytokinetics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- News
- Results
- Results
About Cytokinetics
Pharmaceutical Preparations
Cytokinetics is a biopharmaceutical company dedicated to discovering, developing, and commercializing small-molecule therapeutics targeting muscle biology to treat severe cardiovascular and neuromuscular diseases. Its core research centers on the cytoskeleton and sarcomere mechanics, organized into cardiac and skeletal muscle contractility programs. The company's first commercial product is MYQORZO (aficamten), an oral cardiac myosin inhibitor approved for adults with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics also advances a pipeline of clinical candidates, including omecamtiv mecarbil, ulacamten, and CK-089. Its commercial focus directs therapies toward specialized customer segments, primarily cardiologists, academic centers of excellence, and focused healthcare providers.
Company profile, executives and historyCytokinetics stock: common questions
What is Cytokinetics's stock price?
CYTK closed at $58.53 on Nov 11, 2026, up 4.18% on the day. Over the past 52 weeks it traded between $53.55 and $88.31.
What is Cytokinetics's market cap?
Cytokinetics was worth $8.14B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CYTK's P/E ratio?
Cytokinetics lost money over fiscal 2025 (diluted EPS -$6.54), so it has no meaningful P/E ratio.
How much revenue does Cytokinetics make?
Cytokinetics reported revenue of $113.29M for the twelve months to Sep 30, 2026, up 29.9% from a year earlier.
Does Cytokinetics pay a dividend?
No. Cytokinetics has not paid a cash dividend over the last twelve months.
When does Cytokinetics report earnings next?
Cytokinetics is expected to report Q4 FY2026 results on Feb 23, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CYTK stock performed over the past year?
Including dividends, CYTK returned -12.0% over the past year, against +12.4% for the S&P 500.
How many CYTK shares are sold short?
18M shares were sold short at the latest FINRA report, 12.99% of the float, or 14.2 days of average trading volume.
Who are Cytokinetics's competitors?
Companies most similar to Cytokinetics by business, industry and size include GYRE, AGIO, GOSS, AKBA, FHTX.
See a number that looks wrong?